^
BIOMARKER:

GFI1 36N

i
Other names: GFI1, Growth Factor Independent 1 Transcriptional Repressor, Growth Factor Independent Protein 1, Zinc Finger Protein Gfi-1, Zinc Finger Protein 163, ZNF163, GFI-1, GFI1A, Growth Factor Independent 1 Transcription Repressor, Growth Factor Independence-1, Growth Factor Independent 1, SCN2
Entrez ID:
3ms
THE GERMLINE VARIANT GFI1-36N PROMOTES GENETIC INSTABILITY IN LEUKEMIC CELLS AND OPENS NEW THERAPEUTIC APPROACHES FOR ABOUT 15% OF ALL AML PATIENTS (EHA 2022)
Cell viability assay and colony-forming unit assay were used to examine the response of GFI1-36S and GFI1-36N leukemic cells to palbociclib treatment...This could promote emergence of chromosomal aberrations and hence contribute to genomic instability of leukemic cells (Figure 1). On a therapeutic level, GFI1-36N could possibly be a marker for a specific subset of AML patients that is sensitive to CDK4/6 inhibitors.
Clinical
|
RAD51 (RAD51 Homolog A) • CHEK1 (Checkpoint kinase 1) • CDK2 (Cyclin-dependent kinase 2) • GFI1 (Growth Factor Independent 1 Transcriptional Repressor)
|
GFI1 36N • KMT2A expression
|
Ibrance (palbociclib)
6ms
Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS). (PubMed, Int J Mol Sci)
On a molecular level, curcumin treatment negatively affected open chromatin structure in the GFI1-36N or -KD haematopoietic cells but not GFI1-36S cells. Taken together, our study thus identified a therapeutic role for curcumin treatment in the treatment of AML patients (homo or heterozygous for GFI1-36N or reduced GFI1 expression) and possibly improved therapy outcome.
Journal
|
NUP98 (Nucleoporin 98 And 96 Precursor 2) • GFI1 (Growth Factor Independent 1 Transcriptional Repressor)
|
GFI1 36N
9ms
Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis. (PubMed, Front Oncol)
MM patients carrying gain of 1q21 (≥3 copies) demonstrated poor progression free survival. Furthermore, gene expression analysis implicated a role for GFI1-36N in epigenetic regulation and metabolism, potentially promoting the initiation and progression of MM.
Clinical • Journal
|
GFI1 (Growth Factor Independent 1 Transcriptional Repressor)
|
Chr t(4;14) • GFI1 36N